Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 1.00 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.68 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.68 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.63 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | LOX | P28300 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451790 | 1.00 | LOXL2 (1.00) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| Hydrochloric Acid SCHEMBL307062 | 0.98 | LOXL2 (0.97) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| Hydrochloric Acid SCHEMBL307891 | 0.98 | LOXL2 (0.97) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL27405638 | 0.90 | LOXL2 (0.82) | LOXL2CYP4F2CYP4A11SLC7A5 | |
| SCHEMBL3012713 | 0.86 | LOXL2 (0.76) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL126284 | 0.85 | LOXL2 (0.74) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL70173 | 0.85 | CYP4F2 (0.83) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| Hydrochloric Acid SCHEMBL4447485 | 0.85 | LOXL2 (0.73) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL95887 | 0.84 | LOXL2 (0.72) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 | |
| SCHEMBL31276630 | 0.84 | CYP4F2 (0.75) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025213277-A1 | N1-(3,4-DICHLOROPHENYL)MALEAMIDE DERIVATIVES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-10-16 | — | — | WO | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-115806503-B | Selective histone deacetylase inhibitor and preparation method and application thereof | 中国海洋大学 | 2025-03-07 | — | — | CN | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| CN-113563245-B | Substituted pyrrolidines and their use in medicine | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024201308-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | 주식회사 엘지화학 | 2024-10-03 | — | — | WO | disclosed |
| EP-3784226-B1 | PYRAZOLE-PHENYLAMIDE DERIVATIVES AS INHIBITORS OF THE RHO-ASSOCIATED PROTEIN KINASE ROCK1 AND ROCK2 FOR THE TREATMENT OF CANCER | TRANSLATIONAL DRUG DEV LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-112367982-B | Amide compounds, compositions and methods of treatment as kinase inhibitors | 转化药物开发有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-1192177-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0775133-B1 | NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | MENARINI LAB (ES) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000077030-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-1999012912-A1 | THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 1999-03-18 | — | — | WO | disclosed |
| EP-0817630-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0817630-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5578629-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996030015-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5534537-A | Prodrugs of inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1996-07-09 | — | — | US | disclosed |
| WO-1996004267-A1 | NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | LOXL2 1051/4885CYP4F2 4608/4885CYP4A11 4537/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | LOXL2 2861/4885CYP4F2 821/4885CYP4A11 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.